A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Inclusion Criteria:

- Ability of the participant or his legally authorized representative (e.g., parent or
legal guardian) to understand the purpose and risks of the study and provide signed
and dated informed consent and authorization to use protected health information in
accordance with national and local participant privacy regulations

- Male participants of any age diagnosed with severe hemophilia A (as confirmed from the
medical record)

- Currently diagnosed with high titer inhibitors (historical peak greater than or equal
to (>=) 5 Bethesda units per milliliter (BU/mL), according to medical records)

- Previously treated with any plasma-derived or recombinant conventional or Extended
Half-Life FVIII

Exclusion Criteria:

- Other coagulation disorder(s) in addition to hemophilia A

- Previous immune tolerance induction (ITI)

- History of hypersensitivity or anaphylaxis associated with any factor VIII (FVIII)
administration

- Planned major surgery scheduled during the study unless deferred until after study
completion (minor surgery such as tooth extraction or insertion/replacement of central
venous access device is allowed)

- Abnormal renal function (serum creatinine >1.5 milligram per deciliter (mg/dL) or 2 ×
upper limit of normal (ULN) for participant age based on local laboratory range) as
assessed by local laboratory

- Serum alanine aminotransferase or aspartate aminotransferase > 5 × upper limit of
normal (ULN) as assessed by local laboratory